{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:04:14Z","timestamp":1787637854089,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"am","delay-in-days":285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.neuropharm.2023.109686","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T11:52:30Z","timestamp":1691668350000},"page":"109686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["PYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5604-8239","authenticated-orcid":false,"given":"A.","family":"Caffrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4670-3499","authenticated-orcid":false,"given":"E.","family":"Lavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-4114","authenticated-orcid":false,"given":"R.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-0938","authenticated-orcid":false,"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Chichura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-5656","authenticated-orcid":false,"given":"R.P.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-5605","authenticated-orcid":false,"given":"H.D.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109686_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.regpep.2005.01.005","article-title":"Neuropeptide Y induced modulation of dopamine synthesis in the striatum","volume":"129","author":"Adewale","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.neuropharm.2023.109686_bib2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.neuropharm.2007.01.018","article-title":"Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors","volume":"52","author":"Adewale","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib3","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2023"},{"key":"10.1016\/j.neuropharm.2023.109686_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1749-6632.2003.tb03176.x","article-title":"The gut hormone peptide YY regulates appetite","volume":"994","author":"Batterham","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2023.109686_bib5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109686_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3-36) physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109686_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nature02666","article-title":"Does gut hormone PYY3\u201336 decrease food intake in rodents? (reply)","volume":"430","author":"Batterham","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109686_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature06212","article-title":"PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans","volume":"450","author":"Batterham","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109686_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2006.08.001","article-title":"Critical role for peptide YY in protein-mediated satiation and body-weight regulation","volume":"4","author":"Batterham","year":"2006","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.peptides.2007.11.003","article-title":"PYY(3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats","volume":"29","author":"Blevins","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2023.109686_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0306-4522(98)00039-6","article-title":"Regional distribution of neuropeptide Y Y2 receptor messenger RNA in the human post mortem brain","volume":"86","author":"Caberlotto","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109686_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7620860","article-title":"Predictors of relapse after inpatient opioid detoxification during 1-year follow-up","volume":"2016","author":"Chalana","year":"2016","journal-title":"J Addict"},{"key":"10.1016\/j.neuropharm.2023.109686_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MED.0b013e3282f3f4b1","article-title":"Peptide YY","volume":"15","author":"Chandarana","year":"2008","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.neuropharm.2023.109686_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molmet.2013.03.001","article-title":"Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance","volume":"2","author":"Chandarana","year":"2013","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib16","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.peptides.2006.08.001","article-title":"Dose-dependent effects of peptide YY(3-36) on conditioned taste aversion in rats","volume":"27","author":"Chelikani","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2023.109686_bib17","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1152\/ajpregu.00164.2007","article-title":"Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats","volume":"293","author":"Chelikani","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib18","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1038\/s41598-023-36178-1","article-title":"A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss","volume":"13","author":"Chichura","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109686_bib19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cmet.2011.09.010","article-title":"The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans","volume":"14","author":"De Silva","year":"2011","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1053\/j.gastro.2005.09.001","article-title":"Effect of peptide YY3-36 on food intake in humans","volume":"129","author":"Degen","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/2046-4053-3-105","article-title":"The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol","volume":"3","author":"Dennis","year":"2014","journal-title":"Syst. Rev."},{"key":"10.1016\/j.neuropharm.2023.109686_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110349","article-title":"Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: evidence from preclinical studies","volume":"111","author":"Domin","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109686_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1098-2396(199602)22:2<139::AID-SYN7>3.0.CO;2-E","article-title":"Autoradiographic distribution of [125I]Leu31,Pro34]PYY and [125I]PYY3-36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands","volume":"22","author":"Dumont","year":"1996","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2023.109686_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neubiorev.2020.09.020","article-title":"Sex differences in behavioral and metabolic effects of gene inactivation: the neuropeptide Y and Y receptors in the brain","volume":"119","author":"Eva","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109686_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ijo.2011.126","article-title":"Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass","volume":"36","author":"Fenske","year":"2012","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.neuropharm.2023.109686_bib27","doi-asserted-by":"crossref","first-page":"26758","DOI":"10.1074\/jbc.270.45.26758","article-title":"Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y\/peptide YY Y2 receptor subtype","volume":"270","author":"Gerald","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109686_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/PL00004908","article-title":"Vascular responses to neuropeptide Y are greater in female than male rats","volume":"355","author":"Glenn","year":"1997","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2005.02.003","article-title":"Peripheral administration of PYY3\u201336 produces conditioned taste aversion in mice","volume":"1","author":"Halatchev","year":"2005","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0196-9781(89)90069-7","article-title":"Identification and characterization of the emetic effects of peptide YY","volume":"10","author":"Harding","year":"1989","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2023.109686_bib31","first-page":"1","article-title":"Effect of peptide tyrosine tyrosine (PYY3\u201336) on high fat diet induced obesity and its metabolic hazards in adult albino rats","volume":"26","author":"Hassan","year":"2015","journal-title":"MJMR"},{"key":"10.1016\/j.neuropharm.2023.109686_bib32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/oby.2011.50","article-title":"Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats","volume":"19","author":"Hayes","year":"2011","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109686_bib33","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA","volume":"26","author":"Hernandez","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109686_bib34","doi-asserted-by":"crossref","first-page":"R406","DOI":"10.1152\/ajpregu.00011.2019","article-title":"NPY2 receptor activation in the dorsal vagal complex increases food intake and attenuates CCK-induced satiation in male rats","volume":"316","author":"Huston","year":"2019","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/adb.12014","article-title":"Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats","volume":"19","author":"Kimmey","year":"2014","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.npep.2018.11.004","article-title":"PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice","volume":"73","author":"Kjaergaard","year":"2019","journal-title":"Neuropeptides"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2023.109686_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neuropharm.2008.07.043","article-title":"Neurobiological substrates for the dark side of compulsivity in addiction","volume":"56","author":"Koob","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2202-10-95","article-title":"Gene expression changes following extinction testing in a heroin behavioral incubation model","volume":"10","author":"Kuntz-Melcavage","year":"2009","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109686_bib41","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00213-021-05850-7","article-title":"Escalation and reinstatement of fentanyl self-administration in male and female rats","volume":"238","author":"Malone","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbr.2008.06.023","article-title":"Food deprivation-like effects of neuropeptide Y on heroin self-administration and reinstatement of heroin seeking in rats","volume":"194","author":"Maric","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109686_bib43","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109686_bib44","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012070","article-title":"Opiate-induced molecular and cellular plasticity of ventral tegmental area and locus coeruleus catecholamine neurons","volume":"2","author":"Mazei-Robison","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neuropharm.2023.109686_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnint.2013.00100","article-title":"Effects of sex and deletion of neuropeptide Y2 receptors from GABAergic neurons on affective and alcohol drinking behaviors in mice","volume":"7","author":"McCall","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109686_bib46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.neubiorev.2021.10.026","article-title":"A novel approach to treating opioid use disorders: dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y(2) receptors","volume":"131","author":"Merkel","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109686_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1021\/acs.jmedchem.0c01783","article-title":"Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis","volume":"64","author":"Milliken","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109686_bib48","series-title":"CDER Conversation: Treatment for Opioid Use Disorder","author":"Mitra Ahadpour","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109686_bib49","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/en.2005-0237","article-title":"Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively","volume":"146","author":"Neary","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/pharmrev.121.000367","article-title":"Sex differences in opioid and psychostimulant craving and relapse: a critical review","volume":"74","author":"Nicolas","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109686_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2023.109686_bib52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0306-3623(91)90235-X","article-title":"The effects of chronic administration of morphine on the levels of brain and adrenal catecholamines and neuropeptide Y in rats","volume":"22","author":"Pages","year":"1991","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0306-3623(92)90003-3","article-title":"Brain and adrenal monoamines and neuropeptide Y in codeine tolerant rats","volume":"23","author":"Pages","year":"1992","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib54","series-title":"The Rat Brain in Stereotaxic Coordinates: Hard","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.neuropharm.2023.109686_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00427441","article-title":"Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats","volume":"84","author":"Pettit","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cmet.2019.01.017","article-title":"A long-acting PYY(3-36) analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates","volume":"29","author":"Rangwala","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/oby.2010.136","article-title":"Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats","volume":"19","author":"Reidelberger","year":"2011","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2023.109686_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41386-018-0234-2","article-title":"Relapse to opioid seeking in rat models: behavior, pharmacology and circuits","volume":"44","author":"Reiner","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/dmrr.1154","article-title":"Peptide hormones regulating appetite--focus on neuroimaging studies in humans","volume":"27","author":"Schloegl","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.neuropharm.2023.109686_bib60","doi-asserted-by":"crossref","first-page":"E1248","DOI":"10.1152\/ajpendo.00569.2013","article-title":"Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men","volume":"306","author":"Schmidt","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2023.109686_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jchemneu.2003.07.003","article-title":"Functional autoradiography of neuropeptide Y Y1 and Y2 receptor subtypes in rat brain using agonist stimulated [35S]GTPgammaS binding","volume":"26","author":"Shaw","year":"2003","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2023.109686_bib62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.neuropharm.2023.109686_bib63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2023.109686_bib64","series-title":"National Center for Health, S.","article-title":"Drug overdose deaths in the United States, 2001\u20132021","author":"Spencer","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109686_bib65","series-title":"The Regulation of Appetite by Gut Hormones","author":"Spreckley","year":"2015"},{"key":"10.1016\/j.neuropharm.2023.109686_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/en.2012-1956","article-title":"Possible mechanisms of circulating PYY-induced satiation in male rats","volume":"154","author":"Stadlbauer","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1017\/S1461145713001223","article-title":"The Y2 receptor agonist PYY(3-36) increases the behavioural response to novelty and acute dopaminergic drug challenge in mice","volume":"17","author":"Stadlbauer","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/cne.21046","article-title":"Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals","volume":"499","author":"Stani\u0107","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib69","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/cne.22608","article-title":"Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules","volume":"519","author":"Stani\u0107","year":"2011","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib70","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1210\/en.2005-0473","article-title":"Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice","volume":"146","author":"Talsania","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841873","article-title":"Sex- and dose-dependent differences in the development of an addiction-like phenotype following extended-access fentanyl self-administration","volume":"13","author":"Towers","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nature02665","article-title":"Physiology: does gut hormone PYY3-36 decrease food intake in rodents?","volume":"430","author":"Tsch\u00f6p","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109686_bib73","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109686_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109686_bib75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109686_bib76","doi-asserted-by":"crossref","first-page":"R367","DOI":"10.1152\/ajpregu.00726.2005","article-title":"PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity","volume":"291","author":"Vrang","year":"2006","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109686_bib77","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0006-8993(93)91182-R","article-title":"Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain","volume":"631","author":"Widdowson","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109686_bib79","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109686_bib80","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0022-3565(24)37249-0","article-title":"Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors","volume":"284","author":"Woldbye","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109686_bib81","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109686_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:25:19Z","timestamp":1758439519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823002769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":82,"alternative-id":["S0028390823002769"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109686","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109686"}}